TED: Strabismus - When and How to Operate

Identifier 20240306_nanos_surgical1_01
Title TED: Strabismus - When and How to Operate
Creator Madhura A Tamhankar, MD
Affiliation Scheie Eye Institute, University of Pennsylvania, Philadelphia, Pennsylvania
Subject Thyroid Eye Disease; Restrictive Strabismus; Diplopia; Teprotumumab; Strabismus Surgery
Description Restrictive strabismus with diplopia occurs in 30-50% of patients in thyroid eye disease (TED) due to a decrease in muscle fiber elasticity caused by the direct infiltration of inflammatory cells, related to cytokines and eventually fibrosis of the extra ocular muscle1. Impairment of motility occurs significantly more often in smokers and older patients2. Several extraocular muscles may be affected although single unilateral muscle involvement can also occur. Hypertropia with restricted elevation due to inferior rectus involvement and esotropia with restricted abduction from medial rectus involvement are the most common types of restrictive strabismus in TED3. The lateral rectus and the oblique muscles are the least affected. Early in the process most patients typically adopt a chin-up posture due to a tight inferior rectus muscle. New onset diplopia can also occur after orbital decompression because of changes in muscle pads and orbital anatomy. Esotropia is most common after medial orbital wall decompression due to displacement of the medial recti muscles in the ethmoid sinus.
Date 2024-03
References 1. Bahn RS. Graves' ophthalmopathy. N Engl J Med. Feb 25;362(8):726-38, 2010. 2. Wiersinga WM, Bartalena L. Epidemiology and prevention of Graves' ophthalmopathy. Thyroid. Oct;12(10):855-60, 2002. 3. Dyer JA. The oculorotary muscles in Graves' disease. Trans Am Ophthalmol Soc. 74:425-56, 1976. 4. Douglas RS, Kahaly GJ, Ugradar S, Elflein H, Ponto KA, Fowler BT, Dailey R, Harris GJ, Schiffman J, Tang R, Wester S, Jain AP, Marcocci C, Marinò M, Antonelli A, Eckstein A, Führer-Sakel D, Salvi M, Sile S, Francis-Sedlak M, Holt RJ, Smith TJ. Teprotumumab Efficacy, Safety, and Durability in Longer- Duration Thyroid Eye Disease and Re-treatment: OPTIC-X Study. Ophthalmology. Apr;129(4):438-449, 2022. 5. Douglas RS, Kahaly GJ, Patel A, Sile S, Thompson EHZ, Perdok R, Fleming JC, Fowler BT, Marcocci C, Marinò M, Antonelli A, Dailey R, Harris GJ, Eckstein A, Schiffman J, Tang R, Nelson C, Salvi M, Wester S, Sherman JW, Vescio T, Holt RJ, Smith TJ. Teprotumumab for the Treatment of Active Thyroid Eye Disease. N Engl J Med. Jan 23;382(4):341-352, 2020.
Language eng
Format application/pdf
Format Creation Microsoft PowerPoint
Type Text
Source 2024 North American Neuro-Ophthalmology Society Annual Meeting
Relation is Part of NANOS Annual Meeting 2024: Surgical Challenges in Neuro-Ophthalmology
Collection Neuro-Ophthalmology Virtual Education Library: NANOS Annual Meeting Collection: https://novel.utah.edu/collection/nanos-annual-meeting-collection/
Publisher North American Neuro-Ophthalmology Society
Holding Institution Spencer S. Eccles Health Sciences Library, University of Utah
Rights Management Copyright 2024. For further information regarding the rights to this collection, please visit: https://NOVEL.utah.edu/about/copyright
ARK ark:/87278/s6ycp8qk
Setname ehsl_novel_nam
ID 2593114
Reference URL https://collections.lib.utah.edu/ark:/87278/s6ycp8qk
Back to Search Results